The company has obtained patents covering Gelpell™ technology in key markets, including the US, Canada, UK, Australia and countries of the European Union.
() () investee Harvest One () () has been granted a US patent for its proprietary Gellpell™ technology through the US Patent and Trademark Office.
Through HVT’s wholly-owned subsidiary SantiPharm Ltd, the company has received a patent for the technology in key markets including the United States, Canada, United Kingdom, Australia and countries of the European Union.
Santipharm produces CBD capsules powered by proprietary Gellpell™ technology, which take a different approach to other products on the market.
Gelpell™ capsules embed the full spectrum hemp extract CBD in seamless gelatine microspheres.